Genzyme, Daiichi allow Impax to launch a generic Welchol

06/30/2011 | Reuters

Generic-drug maker Impax Laboratories resolved a patent dispute with Genzyme and Daiichi Sankyo regarding diabetes pill Welchol. The settlement allows Impax to market its version on March 2, 2015, or earlier under certain conditions.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD